...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>ACS applied materials & interfaces >Construction and Evaluation of a Targeted Hyaluronic Acid Nanoparticle/Photosensitizer Complex for Cancer Photodynamic Therapy
【24h】

Construction and Evaluation of a Targeted Hyaluronic Acid Nanoparticle/Photosensitizer Complex for Cancer Photodynamic Therapy

机译：靶向透明质酸纳米粒子/光敏剂复合物癌光动力治疗的施工与评价

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Photodynamic therapy (PDT) is a novel treatment modality that is under intensive preclinical investigations for a variety of diseases, including cancer. Despite extensive studies in this area, selective and effective photodynamic agents that can specifically accumulate in tumors to reach a therapeutic concentration are limited. Although recent attempts have produced photosensitizers (PSs) complexed with various nanomaterials, the tedious preparation steps and poor tumor efficiency of therapy hamper their utilization. Here, we developed a CD44-targeted nanophotodynamic agent by physically encapsulating a photosensitizer, Ce6, into a hyaluronic acid nanoparticle (HANP), which was hereby denoted HANP/Ce6. Its physical features and capability for photodynamic therapy were characterized in vitro and in vivo. Systemic delivery of HANP/Ce6 resulted in its accumulation in a human colon cancer xenograft model. The tumor/muscle ratio reached 3.47 +/- 0.46 at 4 h post injection, as confirmed by fluorescence imaging. Tumor growth after HANP/Ce6 treatment with laser irradiation (0.15 W/cm(2), 630 nm) was significantly inhibited by 9.61 +/- 1.09-fold compared to that in tumor control groups, which showed no change in tumor growth. No apparent systemic and local toxic effects on the mice were observed. HANP/Ce6-mediated tumor growth inhibition was accessed and observed for the first time by F-18-fluoro-2-deoxy-D-glucose positron emission tomography as early as 1 day after treatment and persisted for 14 days within our treatment time window. In sum, our results highlight the imaging properties and therapeutic effects of the novel HANP/Ce6 theranostic nanoparticle for CD44-targeted PDT cancer therapy that may be potentially utilized in the clinic. This HANP system may also be applied for the delivery of other hydrophobic PSs, particularly those that could not be chemically modified.
机译：光动力疗法（PDT）是一种新的治疗方式，对各种疾病的密集临床前调查，包括癌症。尽管在该领域进行了广泛的研究，但是可以在肿瘤中专门积聚以达到治疗浓度的选择性和有效的光动力学剂是有限的。尽管最近的尝试产生了与各种纳米材料复合的光敏剂（PSS），但繁琐的制备步骤和肿瘤肿瘤效率差的疗效妨碍了它们的利用。在这里，我们通过物理地将光敏剂CE6封装到透明质酸纳米粒子（HANP）中，开发了CD44-靶向纳米光动力学剂，其在此表示HANP / CE6。其物理特征和用于光动力疗法的能力在体外和体内表征。汉普/ CE6的全身递送导致其在人结肠癌异种移植模型中的积累。注射后4小时肿瘤/肌肉比达到3.47 +/- 0.46，如荧光成像证实。与肿瘤对照组相比，HanP / Ce6处理后HANP / CE6处理后的肿瘤生长（0.15W / cm（2），630nm）显着抑制了9.61 +/- 1.09折。肿瘤生长没有变化。没有观察到对小鼠的明显全身和局部毒性作用。在治疗后1天，在治疗后1天，通过F-18-Fluoro-2-Deoxy-D-葡萄糖正向葡萄糖正电子曝光断层扫描并在我们的治疗时间窗口中持续14天，首次访问并观察到并观察到并观察到并观察到并观察并观察并观察到并观察到并观察到并观察到并观察到14天。总之，我们的结果突出了新型HANP / CE6 Theranostic纳米粒子用于CD44靶向PDT癌症疗法的成像性质和治疗效果，所述CD44靶向PDT癌症治疗可能是临床潜在的。该HANP系统也可以应用于递送其他疏水PSS，特别是那些不能化学改性的疏水性PSS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号